1. Preface
1.1. Market Definition and Scope
1.2. Key Research Objectives
2. Assumptions and Research Methodology
3. Market Overview
3.1. Overview
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Global Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by End-user
4.1. Introduction & Definition
4.2. Key Findings/Developments
4.3. Market Value Forecast, by End-user, 2017-2031
4.3.1. Biotechnology & Pharmaceutical Companies
4.3.2. Academia
4.3.3. Cosmetic Industry
4.3.4. Contract Research Organizations
4.3.5. Contract Development & Manufacturing Organizations
5. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Therapeutic Area
5.1. Introduction & Definition
5.2. Key Findings/Developments
5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
5.3.1. Oncology & Immune-oncology
5.3.1.1. Small Molecules
5.3.1.2. Protein-based Therapeutics
5.3.1.3. Cell Therapy
5.3.1.4. Nucleic Acid-based Drugs
5.3.2. Cardiovascular & Metabolic Diseases
5.3.2.1. Small Molecules
5.3.2.2. Protein-based Therapeutics
5.3.2.3. Cell Therapy
5.3.2.4. Nucleic Acid-based Drugs
5.3.3. Immunology
5.3.3.1. Small Molecules
5.3.3.2. Protein-based Therapeutics
5.3.3.3. Cell Therapy
5.3.3.4. Nucleic Acid-based Drugs
5.3.4. Rare Diseases
5.3.4.1. Small Molecules
5.3.4.2. Protein-based Therapeutics
5.3.4.3. Cell Therapy
5.3.4.4. Nucleic Acid-based Drugs
5.3.5. Neurological Diseases
5.3.5.1. Small Molecules
5.3.5.2. Protein-based Therapeutics
5.3.5.3. Cell Therapy
5.3.5.4. Nucleic Acid-based Drugs
5.3.6. Others
5.3.6.1. Small Molecules
5.3.6.2. Protein-based Therapeutics
5.3.6.3. Cell Therapy
5.3.6.4. Nucleic Acid-based Drugs
6. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Workplace
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Workplace, 2016-2031
6.3.1. Target Identification
6.3.2. Hit Generation & Lead Identification
6.3.3. Lead Optimization
6.3.4. In Vitro Preclinical Studies
6.3.5. In Vivo Preclinical Studies
6.3.6. Clinical Studies
7. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Country/Region
7.1. Key Findings
7.2. Market Value Forecast, by Country/Region, 2017-2031
7.2.1. U.S.
7.2.2. Europe
7.2.3. China
7.2.4. Rest of the World
8. U.S. Image-based Cytometry in Cell Analysis Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by End-user, 2017-2031
8.2.1. Biotechnology & Pharmaceutical Companies
8.2.2. Academia
8.2.3. Cosmetic Industry
8.2.4. Contract Research Organizations
8.2.5. Contract Development & Manufacturing Organizations
8.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
8.3.1. Oncology & Immune-oncology
8.3.1.1. Small Molecules
8.3.1.2. Protein-based Therapeutics
8.3.1.3. Cell Therapy
8.3.1.4. Nucleic Acid-based Drugs
8.3.2. Cardiovascular & Metabolic Diseases
8.3.2.1. Small Molecules
8.3.2.2. Protein-based Therapeutics
8.3.2.3. Cell Therapy
8.3.2.4. Nucleic Acid-based Drugs
8.3.3. Immunology
8.3.3.1. Small Molecules
8.3.3.2. Protein-based Therapeutics
8.3.3.3. Cell Therapy
8.3.3.4. Nucleic Acid-based Drugs
8.3.4. Rare Diseases
8.3.4.1. Small Molecules
8.3.4.2. Protein-based Therapeutics
8.3.4.3. Cell Therapy
8.3.4.4. Nucleic Acid-based Drugs
8.3.5. Neurological Diseases
8.3.5.1. Small Molecules
8.3.5.2. Protein-based Therapeutics
8.3.5.3. Cell Therapy
8.3.5.4. Nucleic Acid-based Drugs
8.3.6. Others
8.3.6.1. Small Molecules
8.3.6.2. Protein-based Therapeutics
8.3.6.3. Cell Therapy
8.3.6.4. Nucleic Acid-based Drugs
8.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
8.4.1. Target Identification
8.4.2. Hit Generation & Lead Identification
8.4.3. Lead Optimization
8.4.4. In Vitro Preclinical Studies
8.4.5. In Vivo Preclinical Studies
8.4.6. Clinical Studies
9. Europe Image-based Cytometry in Cell Analysis Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by End-user, 2017-2031
9.2.1. Biotechnology & Pharmaceutical Companies
9.2.2. Academia
9.2.3. Cosmetic Industry
9.2.4. Contract Research Organizations
9.2.5. Contract Development & Manufacturing Organizations
9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
9.3.1. Oncology & Immune-oncology
9.3.1.1. Small Molecules
9.3.1.2. Protein-based Therapeutics
9.3.1.3. Cell Therapy
9.3.1.4. Nucleic Acid-based Drugs
9.3.2. Cardiovascular & Metabolic Diseases
9.3.2.1. Small Molecules
9.3.2.2. Protein-based Therapeutics
9.3.2.3. Cell Therapy
9.3.2.4. Nucleic Acid-based Drugs
9.3.3. Immunology
9.3.3.1. Small Molecules
9.3.3.2. Protein-based Therapeutics
9.3.3.3. Cell Therapy
9.3.3.4. Nucleic Acid-based Drugs
9.3.4. Rare Diseases
9.3.4.1. Small Molecules
9.3.4.2. Protein-based Therapeutics
9.3.4.3. Cell Therapy
9.3.4.4. Nucleic Acid-based Drugs
9.3.5. Neurological Diseases
9.3.5.1. Small Molecules
9.3.5.2. Protein-based Therapeutics
9.3.5.3. Cell Therapy
9.3.5.4. Nucleic Acid-based Drugs
9.3.6. Others
9.3.6.1. Small Molecules
9.3.6.2. Protein-based Therapeutics
9.3.6.3. Cell Therapy
9.3.6.4. Nucleic Acid-based Drugs
9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
9.4.1. Target Identification
9.4.2. Hit Generation & Lead Identification
9.4.3. Lead Optimization
9.4.4. In Vitro Preclinical Studies
9.4.5. In Vivo Preclinical Studies
9.4.6. Clinical Studies
9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
9.5.1. EU5
9.5.2. U.K.
9.5.3. Switzerland
9.5.4. Rest of Europe
10. China Image-based Cytometry in Cell Analysis Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by End-user, 2017-2031
10.2.1. Biotechnology & Pharmaceutical Companies
10.2.2. Academia
10.2.3. Cosmetic Industry
10.2.4. Contract Research Organizations
10.2.5. Contract Development & Manufacturing Organizations
10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
10.3.1. Oncology & Immune-oncology
10.3.1.1. Small Molecules
10.3.1.2. Protein-based Therapeutics
10.3.1.3. Cell Therapy
10.3.1.4. Nucleic Acid-based Drugs
10.3.2. Cardiovascular & Metabolic Diseases
10.3.2.1. Small Molecules
10.3.2.2. Protein-based Therapeutics
10.3.2.3. Cell Therapy
10.3.2.4. Nucleic Acid-based Drugs
10.3.3. Immunology
10.3.3.1. Small Molecules
10.3.3.2. Protein-based Therapeutics
10.3.3.3. Cell Therapy
10.3.3.4. Nucleic Acid-based Drugs
10.3.3.5. Nucleic Acid
10.3.4. Rare Diseases
10.3.4.1. Small Molecules
10.3.4.2. Protein-based Therapeutics
10.3.4.3. Cell Therapy
10.3.4.4. Nucleic Acid-based Drugs
10.3.5. Neurological Diseases
10.3.5.1. Small Molecules
10.3.5.2. Protein-based Therapeutics
10.3.5.3. Cell Therapy
10.3.5.4. Nucleic Acid-based Drugs
10.3.6. Others
10.3.6.1. Small Molecules
10.3.6.2. Protein-based Therapeutics
10.3.6.3. Cell Therapy
10.3.6.4. Nucleic Acid-based Drugs
10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
10.4.1. Target Identification
10.4.2. Hit Generation & Lead Identification
10.4.3. Lead Optimization
10.4.4. In Vitro Preclinical Studies
10.4.5. In Vivo Preclinical Studies
10.4.6. Clinical Studies
11. Rest of the World Image-based Cytometry in Cell Analysis Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by End-user, 2017-2031
11.2.1. Biotechnology & Pharmaceutical Companies
11.2.2. Academia
11.2.3. Cosmetic Industry
11.2.4. Contract Research Organizations
11.2.5. Contract Development & Manufacturing Organizations
11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
11.3.1. Oncology & Immune-oncology
11.3.1.1. Small Molecules
11.3.1.2. Protein-based Therapeutics
11.3.1.3. Cell Therapy
11.3.1.4. Nucleic Acid-based Drugs
11.3.2. Cardiovascular & Metabolic Diseases
11.3.2.1. Small Molecules
11.3.2.2. Protein-based Therapeutics
11.3.2.3. Cell Therapy
11.3.2.4. Nucleic Acid-based Drugs
11.3.3. Immunology
11.3.3.1. Small Molecules
11.3.3.2. Protein-based Therapeutics
11.3.3.3. Cell Therapy
11.3.3.4. Nucleic Acid-based Drugs
11.3.4. Rare Diseases
11.3.4.1. Small Molecules
11.3.4.2. Protein-based Therapeutics
11.3.4.3. Cell Therapy
11.3.4.4. Nucleic Acid-based Drugs
11.3.5. Neurological Diseases
11.3.5.1. Small Molecules
11.3.5.2. Protein-based Therapeutics
11.3.5.3. Cell Therapy
11.3.5.4. Nucleic Acid-based Drugs
11.3.6. Others
11.3.6.1. Small Molecules
11.3.6.2. Protein-based Therapeutics
11.3.6.3. Cell Therapy
11.3.6.4. Nucleic Acid-based Drugs
11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
11.4.1. Target Identification
11.4.2. Hit Generation & Lead Identification
11.4.3. Lead Optimization
11.4.4. In Vitro Preclinical Studies
11.4.5. In Vivo Preclinical Studies
11.4.6. Clinical Studies
12. Competition Landscape
12.1. Market Share Analysis, by Company (2022)
12.2. Company Profiles
12.2.1. Nanolive SA
12.2.1.1. Company Overview
12.2.1.2. Product Portfolio/Brands with its Description/Features
12.2.1.3. Strategic Overview/Recent Developments
12.2.1.4. SWOT Analysis
12.2.2. PerkinElmer, Inc.
12.2.2.1. Company Overview
12.2.2.2. Product Portfolio/Brands with its Description/Features
12.2.2.3. Financial Overview
12.2.2.4. Strategic Overview/Recent Developments
12.2.2.5. SWOT Analysis
12.2.3. Sartorius AG
12.2.3.1. Company Overview
12.2.3.2. Product Portfolio/Brands with its Description/Features
12.2.3.3. Financial Overview
12.2.3.4. Strategic Overview/Recent Developments
12.2.3.5. SWOT Analysis
12.2.4. Thermo Fisher Scientific Inc.
12.2.4.1. Company Overview
12.2.4.2. Product Portfolio/Brands with its Description/Features
12.2.4.3. Financial Overview
12.2.4.4. Strategic Overview/Recent Developments
12.2.4.5. SWOT Analysis
12.2.5. Merck KGaA
12.2.5.1. Company Overview
12.2.5.2. Product Portfolio/Brands with its Description/Features
12.2.5.3. Financial Overview
12.2.5.4. Strategic Overview/Recent Developments
12.2.5.5. SWOT Analysis
12.2.6. Charles River Laboratories
12.2.6.1. Company Overview
12.2.6.2. Product Portfolio/Brands with its Description/Features
12.2.6.3. Financial Overview
12.2.6.4. SWOT Analysis
12.2.7. Yokogawa Electric Corporation
12.2.7.1. Company Overview
12.2.7.2. Product Portfolio/Brands with its Description/Features
12.2.7.3. Financial Overview
12.2.7.4. SWOT Analysis
12.2.8. Carl Zeiss AG
12.2.8.1. Company Overview
12.2.8.2. Product Portfolio/Brands with its Description/Features
12.2.8.3. Financial Overview
12.2.8.4. Strategic Overview/Recent Developments
12.2.8.5. SWOT Analysis
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/